Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC

Cardiff Oncology, Inc.

CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.
Phase 2 CRDF-004: onvansertib 30mg + FOLFIRI/bev showed 72.2% ORR vs 43.2% SoC (p=0.051) and PFS HR 0.37 vs SoC (p=0.048).
Company selected 30mg dose of onvansertib with FOLFIRI/bev for registrational program; plans to initiate later in 2026 after FDA consultation.
Final data and registrational plans expected in H1 2026; onvansertib well-tolerated with no additive toxicity.
Conference call today at 8:30 a.m. ET to discuss results and strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.